巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    UroGen Pharma Ltd

    URGN
    5.440
    0.280
    5.43%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・UroGen Pharma Ltd - 延遲價格・最後更新於 27/05 12:14
    最高位
    5.510
    最低位
    5.060
    開市價
    --
    前收市價
    5.160
    成交量(千)
    10.97
    成交額(百萬)
    0.56
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    123.45
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    19.660 - 4.850
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    UroGen Pharma Ltd
    證券代碼
    URGN.US
    所屬板塊
    Biotechnology
    公司業務
    UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy.
    發行量
    22688512
    公司總部
    400 Alexander Park
    公司網址
    https://www.urogen.com
    公司電郵
    investors@urogen.com
    公司電話
    +1 646 768-9780
    暫無內容

    關於

    UroGen Pharma Ltd(URGN.US)所屬的行業板塊為Biotechnology。
    UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy.
    詳細公司背景可參考: https://www.urogen.com